ISGlobal and Novartis: Co-creating solutions for people affected by Chagas disease @Novartis
ISGlobal and Novartis: Co-creating solutions for people affected by Chagas disease  @Novartis
Uploaded April 2022 | Updated November 2026, 2 hours ago
Globally, Chagas disease affects 6 million people, mainly in Latin America, and is a major public health problem in Bolivia. Starting as a parasitic disease, it can lead to chronic cardiac disorders in up to one third of patients. In Bolivia, Novartis is working with the Barcelona Institute for Global Health (ISGlobal) to promote an integrated, comprehensive approach to prevent, treat, and manage Chagas disease.

Listen to Irene Jimeno from ISGlobal talk about the collaboration with Novartis in Bolivia.

Learn more: bit.ly/3rape1Y

©2022 Novartis AG
ISGlobal and Novartis: Co-creating solutions for people affected by Chagas diseaseCelebrating Our Unique Talents Through Music - Gustavo’s storyStrategic Value for ShareholdersSickle cell disease screening a critical step to save lives and improve careDriving the next generation of CAR-T therapyNext Generation Scientist 2023Living with CML: A Patient and Doctor Reflect on Care, Progress and HopeThe Future of Health: Unlocking the power of data to improve urban healthBring your whole self to work at NovartisHow many types of cancer can you name?Keeping a persistent killer on the runNext Generation Scientist 2024
Novartis |

ISGlobal and Novartis: Co-creating solutions for people affected by Chagas disease

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER